Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas | Zendy

Melissa Frizziero | Zendy; Francesca Spada | Zendy; Ángela Lamarca | Zendy; Zoe Kordatou | Zendy; Jorge Barriuso | Zendy; Christiuttall | Zendy; Mairéad G. McNamara | Zendy; Richard Hubner | Zendy; Wasat Mansoor | Zendy; Prakash Manoharan | Zendy; Nicola Fazio | Zendy; Juan W. Valle | Zendy

Open Access

Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas

Author(s) -

Melissa Frizziero,

Francesca Spada,

Ángela Lamarca,

Zoe Kordatou,

Jorge Barriuso,

Christiuttall,

Mairéad G. McNamara,

Richard Hubner,

Wasat Mansoor,

Prakash Manoharan,

Nicola Fazio,

Juan W. Valle

Publication year - 2019

Publication title -

neuroendocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.493

H-Index - 101

eISSN - 1423-0194

pISSN - 0028-3835

DOI - 10.1159/000497336

Subject(s) - medicine , carboplatin , etoposide , gastroenterology , progression free survival , neuroendocrine tumors , stage (stratigraphy) , chemotherapy , oncology , cisplatin , paleontology , biology

Carboplatin-etoposide (CarboEtop) is a 1st-line option for patients with advanced extra-pulmonary (EP), poorly-differentiated (PD) neuroendocrine carcinoma (NEC). Different schedules are used in clinical practice and randomised evidence is lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research